Anuraag Saini

Anuraag Saini

Auto-generated profile, based on publicly available information

Anuraag Saini

Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Infectious Disease Modelling
Verified
Journal Article
Open access
VVVeenapani Verma
Veenapani Verma
ASAnuraag Saini
Anuraag Saini
SGSumirtha Gandhi
Sumirtha Gandhi
UDUmakant Dash
Umakant Dash
SKShaffi Fazaludeen Koya
Shaffi Fazaludeen Koya
Due to uncertainties encompassing the transmission dynamics of COVID-19, mathematical models informing the trajectory of disease are being proposed throughout the world. Current pandemic is also characterized by surge in hospitalizations which has overwhelmed even the most resilient health systems. Therefore, it is imperative to assess health system preparedness in tandem with need projections for comprehensive outlook. We attempted this study to forecast the need for hospital resources for one year period and correspondingly assessed capacity and tipping points of Indian health system to absorb surges in need due to COVID-19. We employed age-structured deterministic SEIR model and modified it to allow for testing and isolation capacity to forecast the need under varying scenarios. Projections for documented cases were made for varying degree of containment and mitigation strategies. Correspondingly, data on health resources was collated from various government records. Further, we computed daily turnover of each of these resources which was then adjusted for proportion of cases requiring mild, severe and critical care to arrive at maximum number of COVID-19 cases manageable by health care system of India. Our results revealed pervasive deficits in the capacity of public health system to absorb surge in need during peak of epidemic. Also, model suggests that continuing strict lockdown measures in India after mid-May 2020 would have been ineffective in suppressing total infections significantly. Augmenting testing to 1,500,000 tests per day during projected peak (mid-September) under social-distancing measures and current test to positive rate of 9.7% would lead to more documented cases (60, 000, 000 to 90, 000, 000) culminating to surge in demand for hospital resources. A minimum allocation of 13x, 70x and 37x times more beds for mild cases, ICU beds and mechanical ventilators respectively would be required to commensurate with need under that scenario. However, if testing capacity is limited to 9,000,000 tests per day (current situation as of 19th August 2020) under continued social-distancing measures, documented cases would plummet significantly, still requiring 5x, 31x and 16x times the current allocated resources (beds for mild cases, ICU beds and mechanical ventilators respectively) to meet unmet need for COVID-19 treatment in India.

29 October 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
ASAnuraag Saini
Anuraag Saini
AFAli Farnoud
Ali Farnoud
Quantitative Systems Pharmacology (QSP) is a powerful approach to provide decision‐making support throughout the drug development process. QSP comes with many challenges in model development, validation, and applications. Traditional QSP workflows are limited by slow knowledge integration, labor‐intensive model construction, inconsistent validation practices, and restricted scalability. In this work, we introduce QSP‐Copilot, the first end‐to‐end AI‐augmented solution designed to improve QSP modeling workflows by integrating a multi‐agent system utilizing large language models (LLMs). QSP‐Copilot provides modular support from project scoping and model structuring to model evaluation and reporting. Through the automation of routine tasks, QSP‐Copilot reduces model development time by approximately 40% and improves methodological transparency through systematic documentation of literature sources and modeling assumptions. We demonstrate QSP‐Copilot's application for two rare diseases of blood coagulation and Gaucher disease. In the blood coagulation case, automated extraction from ten peer‐reviewed articles yielded 179 biological entity interaction pairs; out of these, only 105 unique mechanisms were retained after standardization. For Gaucher disease, screening nine articles produced 151 pairs, which were consolidated into 68 distinct biological interactions following the same post‐processing workflow. The extraction precision for blood coagulation and Gaucher disease is 99.1% and 100.0%, respectively. QSP‐Copilot extractions can be incorporated into effect diagrams with minimal expert filtering, significantly reducing the manual curation burden. The integration of AI‐augmented workflows like QSP‐Copilot represents a pivotal shift toward enhanced scalability and impact for QSP across the drug development pipelines, especially in disease areas where biological knowledge is sparse, such as rare diseases.

19 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
VVVeenapani Verma
Veenapani Verma
ASAnuraag Saini
Anuraag Saini
SGSumirtha Gandhi
Sumirtha Gandhi
UDUmakant Dash
Umakant Dash
MKMuhammad Shaffi Fazaludeen Koya
Muhammad Shaffi Fazaludeen Koya
BACKGROUND: Due to uncertainties encompassing the transmission dynamics of COVID-19, mathematical models informing the trajectory of disease are being proposed throughout the world. Current pandemic is also characterized by surge in hospitalizations which has overwhelmed even the most resilient health systems. Therefore, it is imperative to assess supply side preparedness in tandem with demand projections for comprehensive outlook. OBJECTIVE: Hence, we attempted this study to forecast the demand of hospital resources for one year period and correspondingly assessed capacity and tipping points of Indian health system to absorb surges in demand due to COVID-19. METHODS: We employed age-structured deterministic SEIR model and modified it to allow for testing and isolation capacity to forecast the demand under varying scenarios. Projections for documented cases were made for varying degree of mitigation strategies of a) No-lockdown b) Moderate-lockdown c) Full-lockdown. Correspondingly, data on a) General beds b) ICU beds and c) Ventilators was collated from various government records. Further, we computed the daily turnover of each of these resources which was then adjusted for proportion of cases requiring mild, severe and critical care to arrive at maximum number of COVID-19 cases manageable by health care system of India. FINDINGS: Our results revealed pervasive deficits in the capacity of public health system to absorb surge in demand during peak of epidemic. Also, continuing strict lockdown measures was found to be ineffective in suppressing total infections significantly, rather would only push the peak by a month. However, augmented testing of 500,000 tests per day during peak (mid-July) under moderate lockdown scenario would lead to more reported cases (5,500,000–6,000,000), leading to surge in demand for hospital resources. A minimum allocation of 10% public resources and 30% private resources would be required to commensurate with demand under that scenario. However, if the testing capacity is limited to 200,000 tests per day under same scenario, documented cases would plummet by half.

13 November 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
APAna Victoria Ponce‐Bobadilla
Ana Victoria Ponce‐Bobadilla
DBDominic Bräm
Dominic Bräm
AFAli Farnoud
Ali Farnoud
Holger FröhlichHolger Fröhlich
Holger Fröhlich
AJAlexander Janssen
Alexander Janssen
SMSven Mensing
Sven Mensing